依帕司他联合羟苯磺酸钙治疗糖尿病视网膜病变的疗效观察

目的观察醛糖还原酶抑制剂对糖尿病视网膜病变的疗效观察。方法 52例非增殖期糖尿病视网膜病变患者随机分为观察组和对照组,两组均给予羟苯磺酸钙及糖尿病组合治疗,在此基础上,观察组予以依帕司他口服,观察两组治疗前后眼底变化情况。结果视网膜病变好转：观察组48.94%（23/47眼）,对照组29.17%（14/48眼）;视网膜病变进展：观察组10.64%（5/47眼）,对照组20.83%（10/48眼）,观察组视网膜病变治疗的有效率高于对照组（P=0.0185,P〈0.05）。结论依帕司他联合羟苯磺酸钙治疗糖尿病视网膜病变较单药治疗效果更好。

Effects of epalrestat combining calcium dobesilate in the treatment of diabetic retinopathy

Objective To observe the efficacy of aldose reductase inhibitor for diabetic retinopathy. Methods 52 patients with non-proliferative diabetic retinopathy patients were randomly divided into observation group and the control group, both groups were given the calcium dobesilate and diabetes combination therapy, on this basis, the observation group was given oral administration of epalrestat, the fundus changes were observed before and after treatment. Results Improved retinopathy： the observation group 48.94% （23/47 eyes）, control group 29.17% （14/48 eyes）; progression of retinopathy： the observation group 10.64% （5/47 eyes）, control group 20.83% （10/48 eyes）; the observation group retinopathy treatment efficiency was higher than that in the control group （P=0.0185,P＆lt;0.05）. Conclusion Epalrestat joint the calcium dobesilate treatment of diabetic retinopathy compared with monotherapy is better.